Results 121 to 130 of about 5,337 (191)

Treating dementia with brain amyloid medications. [PDF]

Can Fam Physician
Kolber MR, Korownyk CS.
europepmc   +1 more source

Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study. [PDF]

J Manag Care Spec Pharm
Dangpiaei S, Kamal KM, Shoair OA, Al-Mamun MA.   +3 more
europepmc   +1 more source

Anti-amyloid immunotherapy and brain volume trajectories in early-onset versus late-onset Alzheimer's disease. [PDF]

Alzheimers Dement (Amst)
Mehta RI, Jaisa-Aad M, Teixeira CVL, Worhunsky PD, Malone JE, Ward M, Keith CM, Phelps HE, Sharif K, Pockl S, Rajabalee N, Marano GD, Bojarski L, Smith S, Massey KM, Hatfield M, D'Haese PF, Rezai AR, Haut MW.   +18 more
europepmc   +1 more source

Aducanumab binding to Aβ_1-42 fibrils alters dynamics of the N-terminal tail while preserving the fibril core. [PDF]

Proc Natl Acad Sci U S A
Palani RS, Williams CG, Thacker D, Silvers R, Qian F, Weinreb PH, Mueller LJ, Linse S, Griffin RG.   +8 more
europepmc   +1 more source

Sex differences in efficacy/safety of anti-amyloid-beta monoclonal antibodies for the treatment of Alzheimer's disease. [PDF]

Transl Clin Pharmacol
Lim S, Lee HW, Yoon S, Han JW, Chung JY, Yoon S.   +5 more
europepmc   +1 more source

Evaluating the safety of investigational anti-Alzheimer's drugs: a comprehensive meta-analysis in the past to current decade. [PDF]

Dement Neuropsychol
Shaik NS, Balya H, Ramamurthy S, Pandiyan B, Elias JM, Gunturu S.   +5 more
europepmc   +1 more source

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now? [PDF]

Int J Mol Sci
Higgins M, Wasef V, Kwakowsky A.
europepmc   +1 more source

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology study. [PDF]

Front Pharmacol
Geerts H, Short SM, Grant A, van der Graaf PH.   +3 more
europepmc   +1 more source

Structural and Functional Determinants of ARIA-H Risk in Anti-Amyloid Monoclonal Antibodies: A Comparative Mechanistic Framework for Alzheimer's Immunotherapy Development. [PDF]

Curr Neuropharmacol
An D, Zou X, Xu Y.
europepmc   +1 more source

Network meta-analysis of the efficacy of nine drugs for cognitive function in patients with Alzheimer's disease. [PDF]

J Alzheimers Dis Rep
Huang S, Guo Y.
europepmc   +1 more source